ASCO GU26 special: Prof. Karam discusses the results of the LITESPARK-022 study
In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Prof. Jose Karam on the results of the LITESPARK-022 study: Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomised phase 3 LITESPARK-022 study.
The LITESPARK-022 study will be also presented and discussed at the upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study.
This interview was recorded at ASCO GU26. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
Contact our organiser
Email: educationonline@uroweb.org